12
Participants
Start Date
March 11, 2025
Primary Completion Date
June 25, 2025
Study Completion Date
June 30, 2025
Treatment A: Arsenic Trioxide (ATO) Intravenous
0.15 mg/kg 2-hour IV infusion of ATO administered under fasted state in single dose
Treatment B: SDK001 (Arsenic Trioxide Oral solution) under faster state
0.15 mg/kg SDK001 administered orally under fasted state in single dose
Treatment C: SDK001 (Arsenic Trioxide Oral solution) under fed state
0.15 mg/kg SDK001 administered orally under fed state (high fat breakfast) in single dose
Treatment D: SDK001 (Arsenic Trioxide Oral solution) with calcium carbonate
0.15 mg/kg SDK001 administered orally with calcium carbonate in tablet form (1g) under fasted state in single dose
The University of Hong Kong-Clinical Trial Centre Phase 1 Centre, Hong Kong
The University of Hong Kong
OTHER
SDK Therapeutics, Inc.
INDUSTRY